{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:18:15Z","timestamp":1780546695346,"version":"3.54.1"},"reference-count":78,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>\n<jats:bold>Background:<\/jats:bold> Although patients with neuroendocrine tumors (NETs) are known to have prolonged overall survival, the contribution of cancer-specific and noncancer deaths is undefined. This study examined cancer-specific and noncancer death after NET diagnosis. <jats:bold>Methods:<\/jats:bold> We conducted a population-based retrospective cohort study of adult patients with NETs from 2001 through 2015. Using competing risks methods, we estimated the cumulative incidence of cancer-specific and noncancer death and stratified by primary NET site and metastatic status. Subdistribution hazard models examined prognostic factors. <jats:bold>Results:<\/jats:bold> Among 8,607 included patients, median follow-up was 42 months (interquartile range, 17\u201382). Risk of cancer-specific death was higher than that of noncancer death, at 27.3% (95% CI, 26.3%\u201328.4%) and 5.6% (95% CI, 5.1%\u20136.1%), respectively, at 5 years. Cancer-specific deaths largely exceeded noncancer deaths in synchronous and metachronous metastatic NETs. Patterns varied by primary tumor site, with highest risks of cancer-specific death in bronchopulmonary and pancreatic NETs. For nonmetastatic gastric, small intestine, colonic, and rectal NETs, the risk of noncancer death exceeded that of cancer-specific deaths. Advancing age, higher material deprivation, and metastases were independently associated with higher hazards, and female sex and high comorbidity burden with lower hazards of cancer-specific death. <jats:bold>Conclusions:<\/jats:bold> Among all NETs, the risk of dying of cancer was higher than that of dying of other causes. Heterogeneity exists by primary NET site. Some patients with nonmetastatic NETs are more likely to die of noncancer causes than of cancer causes. This information is important for counseling, decision-making, and design of future trials. Cancer-specific mortality should be included in outcomes when assessing treatment strategies.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7666","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T16:01:54Z","timestamp":1629475314000},"page":"935-944","source":"Crossref","is-referenced-by-count":14,"title":["Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis"],"prefix":"10.6004","volume":"19","author":[{"given":"Julie","family":"Hallet","sequence":"first","affiliation":[{"name":"1Faculty of Medicine, University of Toronto, Toronto, Ontario;"},{"name":"2Susan Leslie Clinic for Neuroendocrine Tumors\u2013Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario;"},{"name":"3ICES, Toronto, Ontario;"},{"name":"4Cancer Program\u2013Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Law","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, University of Toronto, Toronto, Ontario;"},{"name":"2Susan Leslie Clinic for Neuroendocrine Tumors\u2013Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario;"},{"name":"4Cancer Program\u2013Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, University of Toronto, Toronto, Ontario;"},{"name":"2Susan Leslie Clinic for Neuroendocrine Tumors\u2013Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario;"},{"name":"3ICES, Toronto, Ontario;"},{"name":"4Cancer Program\u2013Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Mahar","sequence":"additional","affiliation":[{"name":"5Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Myrehaug","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, University of Toronto, Toronto, Ontario;"},{"name":"2Susan Leslie Clinic for Neuroendocrine Tumors\u2013Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario;"},{"name":"4Cancer Program\u2013Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Zuk","sequence":"additional","affiliation":[{"name":"4Cancer Program\u2013Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"3ICES, Toronto, Ontario;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Chan","sequence":"additional","affiliation":[{"name":"3ICES, Toronto, Ontario;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Assal","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, University of Toronto, Toronto, Ontario;"},{"name":"2Susan Leslie Clinic for Neuroendocrine Tumors\u2013Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Coburn","sequence":"additional","affiliation":[{"name":"1Faculty of Medicine, University of Toronto, Toronto, Ontario;"},{"name":"2Susan Leslie Clinic for Neuroendocrine Tumors\u2013Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario;"},{"name":"3ICES, Toronto, Ontario;"},{"name":"4Cancer Program\u2013Clinical Evaluative Sciences, Sunnybrook Research Institute, Toronto, Ontario; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref331","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/annonc\/mdx164","article-title":"Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors","volume":"28","author":"Shen","year":"2017","journal-title":"Ann Oncol"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpg.2013.01.006","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine tumours","volume":"26","author":"Fraenkel","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","article-title":"Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations","volume":"32","author":"Hurria","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s11605-019-04433-4","article-title":"A survival analysis of patients with localized, asymptomatic pancreatic neuroendocrine tumors: no surgical survival benefit when examining appropriately selected outcomes.","volume":"24","author":"Powers","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"ref171","first-page":"246","article-title":"Cancer registration in Ontario: a computer approach","author":"Clarke","year":"1991","journal-title":"IARC Sci Publ"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/annonc\/mdj007","article-title":"Origins of socio-economic inequalities in cancer survival: a review","volume":"17","author":"Woods","year":"2006","journal-title":"Ann Oncol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jamaoncol.2018.2428","article-title":"Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Singh","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/MEG.0000000000001350","article-title":"Competing risks and cause-specific mortality in patients with pancreatic neuroendocrine tumors","volume":"31","author":"Li","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00005650-199105000-00006","article-title":"Development and application of a population-oriented measure of ambulatory care case-mix","volume":"29","author":"Weiner","year":"1991","journal-title":"Med Care"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/cncr.25427","article-title":"The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada","volume":"116","author":"Booth","year":"2010","journal-title":"Cancer"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jss.2019.04.002","article-title":"Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors","volume":"243","author":"Ye","year":"2019","journal-title":"J Surg Res"},{"key":"ref581","first-page":"246","article-title":"Cancer registration in Ontario: a computer approach","author":"Clarke","year":"1991","journal-title":"IARC Sci Publ"},{"key":"ref601","article-title":"Government of Act Accessed Available at https www canada ca en health canada services health care system canada health care system medicare canada health act html","volume":"21","author":"Canada","year":"2019","journal-title":"Health"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/annonc\/mdx164","article-title":"Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors","volume":"28","author":"Shen","year":"2017","journal-title":"Ann Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EC-18-0485","article-title":"The impact of surgery in metastatic pancreatic neuroendocrine tumors: a competing risk analysis","volume":"8","author":"He","year":"2019","journal-title":"Endocr Connect"},{"key":"ref91","first-page":"e5595","article-title":"Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes","volume-title":"BMJ","volume":"346","author":"Hemingway","year":"2013"},{"key":"ref501","first-page":"e5595","article-title":"Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes","volume-title":"BMJ","volume":"346","author":"Hemingway","year":"2013"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2105\/AJPH.82.5.703","article-title":"Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology","volume":"82","author":"Krieger","year":"1992","journal-title":"Am J Public Health"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","article-title":"Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials","volume":"23","author":"Townsley","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref191","article-title":"Government of Act Accessed Available at https www canada ca en health canada services health care system canada health care system medicare canada health act html","volume":"21","author":"Canada","year":"2019","journal-title":"Health"},{"key":"ref641","first-page":"52","article-title":"Measuring \u201crurality\u201d for purposes of health-care planning: an empirical measure for Ontario","volume":"33","author":"Karlj","year":"2009","journal-title":"Ont Med Rev"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1007\/BF03403823","article-title":"Development of the Canadian Marginalization Index: a new tool for the study of inequality","volume":"103","author":"Matheson","year":"2012","journal-title":"Can J Pub Health"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLOS Med"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/1475-6773.01029","article-title":"Assessing population health care need using a claims-based ACG morbidity measure: a validation analysis in the Province of Manitoba","volume":"37","author":"Reid","year":"2002","journal-title":"Health Serv Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jamaoncol.2017.0575","article-title":"Understanding neuroendocrine tumors: a NET gain","volume":"3","author":"Kunz","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/cncr.29338","article-title":"Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLOS Med"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bjs.10333","article-title":"Clinical signs of fibrosis in small intestinal neuroendocrine tumours","volume":"104","author":"Daskalakis","year":"2016","journal-title":"Br J Surg"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2105\/AJPH.82.5.703","article-title":"Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology","volume":"82","author":"Krieger","year":"1992","journal-title":"Am J Public Health"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.32648","article-title":"Causes of death after breast cancer diagnosis: a US population-based analysis","volume":"126","author":"Afifi","year":"2020","journal-title":"Cancer"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration","volume":"41","author":"Robles","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/cncr.25427","article-title":"The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada","volume":"116","author":"Booth","year":"2010","journal-title":"Cancer"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canep.2019.02.004","article-title":"Improving the reporting of cancer-specific mortality and survival in research using cancer registry data","volume":"59","author":"Wissing","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jamaoncol.2017.0575","article-title":"Understanding neuroendocrine tumors: a NET gain","volume":"3","author":"Kunz","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1007\/BF03403823","article-title":"Development of the Canadian Marginalization Index: a new tool for the study of inequality","volume":"103","author":"Matheson","year":"2012","journal-title":"Can J Pub Health"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration","volume":"41","author":"Robles","year":"1988","journal-title":"J Clin Epidemiol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejso.2016.10.031","article-title":"Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver","volume":"43","author":"Citterio","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005650-200101000-00010","article-title":"Performance of the ACG case-mix system in two Canadian provinces","volume":"39","author":"Reid","year":"2001","journal-title":"Med Care"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jamaoncol.2018.2428","article-title":"Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors","volume":"4","author":"Singh","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpg.2013.01.006","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine tumours","volume":"26","author":"Fraenkel","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00005650-199105000-00006","article-title":"Development and application of a population-oriented measure of ambulatory care case-mix","volume":"29","author":"Weiner","year":"1991","journal-title":"Med Care"},{"key":"ref211","first-page":"16","article-title":"Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients","volume":"30","author":"Brenner","year":"2009","journal-title":"Chronic Dis Can"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jss.2019.04.002","article-title":"Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors","volume":"243","author":"Ye","year":"2019","journal-title":"J Surg Res"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005650-200101000-00010","article-title":"Performance of the ACG case-mix system in two Canadian provinces","volume":"39","author":"Reid","year":"2001","journal-title":"Med Care"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.3747\/co.35.3930","article-title":"Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter?","volume":"25","author":"Hallet","year":"2018","journal-title":"Curr Oncol"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/MEG.0000000000001350","article-title":"Competing risks and cause-specific mortality in patients with pancreatic neuroendocrine tumors","volume":"31","author":"Li","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejso.2016.10.031","article-title":"Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver","volume":"43","author":"Citterio","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s11605-019-04433-4","article-title":"A survival analysis of patients with localized, asymptomatic pancreatic neuroendocrine tumors: no surgical survival benefit when examining appropriately selected outcomes.","volume":"24","author":"Powers","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/annonc\/mdj007","article-title":"Origins of socio-economic inequalities in cancer survival: a review","volume":"17","author":"Woods","year":"2006","journal-title":"Ann Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.32648","article-title":"Causes of death after breast cancer diagnosis: a US population-based analysis","volume":"126","author":"Afifi","year":"2020","journal-title":"Cancer"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","article-title":"Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations","volume":"32","author":"Hurria","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.3747\/co.35.3930","article-title":"Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter?","volume":"25","author":"Hallet","year":"2018","journal-title":"Curr Oncol"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1200\/JCO.2005.00.141","article-title":"Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials","volume":"23","author":"Townsley","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/1475-6773.01029","article-title":"Assessing population health care need using a claims-based ACG morbidity measure: a validation analysis in the Province of Manitoba","volume":"37","author":"Reid","year":"2002","journal-title":"Health Serv Res"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bjs.10333","article-title":"Clinical signs of fibrosis in small intestinal neuroendocrine tumours","volume":"104","author":"Daskalakis","year":"2016","journal-title":"Br J Surg"},{"key":"ref621","first-page":"16","article-title":"Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients","volume":"30","author":"Brenner","year":"2009","journal-title":"Chronic Dis Can"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canep.2019.02.004","article-title":"Improving the reporting of cancer-specific mortality and survival in research using cancer registry data","volume":"59","author":"Wissing","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EC-18-0485","article-title":"The impact of surgery in metastatic pancreatic neuroendocrine tumors: a competing risk analysis","volume":"8","author":"He","year":"2019","journal-title":"Endocr Connect"},{"key":"ref231","first-page":"52","article-title":"Measuring \u201crurality\u201d for purposes of health-care planning: an empirical measure for Ontario","volume":"33","author":"Karlj","year":"2009","journal-title":"Ont Med Rev"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/cncr.29338","article-title":"Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/8\/article-p935.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/19\/8\/article-p935.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T18:38:24Z","timestamp":1636742304000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/8\/article-p935.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":78,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7666","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}